Thursday, January 27, 2022 from 2:00 PM ET to 3:00 PM ET • Hosted jointly by AST's Kidney Pancreas Community of Practice (KPCOP) and Transplant Pharmacy Community of Practice (TxPharm COP)
"Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes)"
(Clinical Trial > Transplantation. 2021 Aug 1;105(8):1808-1817. doi: 10.1097/TP.0000000000003496.)
In this article:
Highly HLA sensitized patients have limited access to life-saving kidney transplantation because of a paucity of immunologically suitable donors. Imlifidase is a cysteine protease that cleaves IgG leading to a rapid decrease in antibody level and inhibition of IgG-mediated injury. This study investigates the efficacy and safety of imlifidase in converting a positive crossmatch test to negative, allowing highly sensitized patients to be transplanted with a living or deceased donor kidney.
- Bonnie Lonze, MD, PhD • New York University Langone Transplant Institute, New York, NY
- Edmund Huang, MD, FAST • Cedars-Sinai Medical Center, Los Angeles, CA
- Christopher Ensor, PharmD, FAST • AdventHealth Orlando, Orlando, FL
AST/AJT Journal Clubs are free, but registration is required.
Archive coming soon.